Patents Assigned to Abmuno Therapeutics LLC
  • Antibodies to TIGIT
    Patent number: 11723971
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 15, 2023
    Assignees: JN Biosciences, LLC, Abmuno Therapeutics, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
  • Antibodies to TIGIT
    Patent number: 10537633
    Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 21, 2020
    Assignees: JN Biosciences LLC, Abmuno Therapeutics LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad